{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:23:51Z","timestamp":1794072231432,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14575-1","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:42:49Z","timestamp":1752504169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Azka","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hameer Khan","family":"Khaskheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izza","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameen","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Shahzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman Sayed","family":"Al Komi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abbas","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"3","key":"14575_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"14575_CR2","first-page":"1288","volume":"20","author":"EM Schaeffer","year":"2022","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023. J Natl Compr Cancer Netw. 2022;20(12):1288\u201398.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"14575_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Curr Treat Options Oncol. 2024;25(7):914\u201331.","journal-title":"Curr Treat Options Oncol"},{"issue":"15","key":"14575_CR4","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.3390\/cancers14153744","volume":"14","author":"Y Mao","year":"2022","unstructured":"Mao Y, Yang G, Li Y, Liang G, Xu W, Hu M. Advances in the current understanding of the mechanisms governing the acquisition of castration-resistant prostate cancer. Cancers. 2022;14(15):3744.","journal-title":"Cancers"},{"issue":"13","key":"14575_CR5","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3390\/cancers15133308","volume":"15","author":"QH Chen","year":"2023","unstructured":"Chen QH. Crosstalk between microtubule stabilizing agents and prostate cancer. Cancers. 2023;15(13):3308.","journal-title":"Cancers"},{"key":"14575_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.crimmu.2023.100068","volume":"4","author":"O Mukherjee","year":"2023","unstructured":"Mukherjee O, Rakshit S, Shanmugam G, Sarkar K. Role of chemotherapeutic drugs in immunomodulation of cancer. Curr Res Immunol. 2023;4: 100068.","journal-title":"Curr Res Immunol"},{"key":"14575_CR7","doi-asserted-by":"publisher","first-page":"110214","DOI":"10.1016\/j.intimp.2023.110214","volume":"119","author":"R Gupta","year":"2023","unstructured":"Gupta R, Kadhim MM, TurkiJalil A, QasimAlasheqi M, Alsaikhan F, KhalimovnaMukhamedova N, et al. The interactions of docetaxel with tumor microenvironment. Int Immunopharmacol. 2023;119:110214.","journal-title":"Int Immunopharmacol"},{"key":"14575_CR8","doi-asserted-by":"publisher","first-page":"114392","DOI":"10.1016\/j.biopha.2023.114392","volume":"160","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023;160:114392.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"14575_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial. Lancet Oncol. 2019;20(10):1432\u201343.","journal-title":"Lancet Oncol"},{"key":"14575_CR10","doi-asserted-by":"publisher","first-page":"102818","DOI":"10.1016\/j.ctrv.2024.102818","volume":"130","author":"E Akkus","year":"2024","unstructured":"Akkus E, Arslan \u00c7, \u00dcr\u00fcn Y. Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: insights and perspectives. Cancer Treat Rev. 2024;130:102818.","journal-title":"Cancer Treat Rev"},{"key":"14575_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 2024;601: 217155.","journal-title":"Cancer Lett"},{"issue":"6","key":"14575_CR12","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.3390\/curroncol30060432","volume":"30","author":"FM Maselli","year":"2023","unstructured":"Maselli FM, Giuliani F, Laface C, Perrone M, Melaccio A, De Santis P, et al. Immunotherapy in prostate cancer: state of art and new therapeutic perspectives. Curr Oncol. 2023;30(6):5769\u201394.","journal-title":"Curr Oncol"},{"key":"14575_CR13","doi-asserted-by":"crossref","unstructured":"Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, et al. A phase 1\/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2024. Available from: https:\/\/www.nature.com\/articles\/s41391-024-00798-z. Cited 2024 Nov 20.","DOI":"10.1038\/s41391-024-00798-z"},{"key":"14575_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","volume":"160","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Gonz\u00e1lez Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, et al. Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61\u201371.","journal-title":"Eur J Cancer"},{"issue":"1","key":"14575_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu EY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM, et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study. Eur Urol. 2022;82(1):22\u201330.","journal-title":"Eur Urol"},{"issue":"1","key":"14575_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41416-022-01991-4","volume":"128","author":"A Rodriguez-Vida","year":"2023","unstructured":"Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, et al. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. Br J Cancer. 2023;128(1):21\u20139.","journal-title":"Br J Cancer"},{"issue":"3","key":"14575_CR17","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.clgc.2014.12.004","volume":"13","author":"RR Aggarwal","year":"2015","unstructured":"Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, et al. Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: a department of defense prostate cancer clinical trials consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. Clin Genitourin Cancer. 2015;13(3):e191\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"14575_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jcyt.2017.01.007","volume":"19","author":"P Kongsted","year":"2017","unstructured":"Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met \u00d6, et al. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy. 2017;19(4):500\u201313.","journal-title":"Cytotherapy"},{"issue":"4","key":"14575_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, et al. Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial. JAMA Oncol. 2022;8(4):546.","journal-title":"JAMA Oncol"},{"issue":"14","key":"14575_CR20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol. 2025;43(14):1638\u201349.","journal-title":"J Clin Oncol"},{"issue":"5","key":"14575_CR21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.euo.2020.10.010","volume":"4","author":"I Heidegger","year":"2021","unstructured":"Heidegger I, Necchi A, Pircher A, Tsaur I, Marra G, Kasivisvanathan V, et al. A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy? Eur Urol Oncol. 2021;4(5):745\u201354.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"14575_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jpm12010008","volume":"12","author":"O Fahmy","year":"2021","unstructured":"Fahmy O, Alhakamy NA, Khairul-Asri MG, Ahmed OAA, Fahmy UA, Fresta CG, et al. Oncological response and predictive biomarkers for the checkpoint inhibitors in castration-resistant metastatic prostate cancer: a systematic review and meta-analysis. J Pers Med. 2021;12(1):8.","journal-title":"J Pers Med"},{"issue":"31","key":"14575_CR23","doi-asserted-by":"publisher","first-page":"e29715","DOI":"10.1097\/MD.0000000000029715","volume":"101","author":"XH Wang","year":"2022","unstructured":"Wang XH, Wang ZQ, Mu ZY, Zhu LP, Zhong CF, Guo S. The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2022;101(31):e29715.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"14575_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00262-013-1457-z","volume":"62","author":"R Harrop","year":"2013","unstructured":"Harrop R, Chu F, Gabrail N, Srinivas S, Blount D, Ferrari A. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA\u20135T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother. 2013;62(9):1511\u201320.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"14575_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","volume":"12","author":"PM Arlen","year":"2006","unstructured":"Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12(4):1260\u20139.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"14575_CR26","doi-asserted-by":"publisher","first-page":"18192","DOI":"10.18632\/oncotarget.4145","volume":"6","author":"M Podrazil","year":"2015","unstructured":"Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, et al. Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015;6(20):18192\u2013205.","journal-title":"Oncotarget"},{"issue":"8","key":"14575_CR27","doi-asserted-by":"publisher","first-page":"e002931","DOI":"10.1136\/jitc-2021-002931","volume":"9","author":"T Dorff","year":"2021","unstructured":"Dorff T, Hirasawa Y, Acoba J, Pagano I, Tamura D, Pal S, et al. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. J Immunother Cancer. 2021;9(8):e002931.","journal-title":"J Immunother Cancer"},{"key":"14575_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00030","volume":"1","author":"M Khunger","year":"2017","unstructured":"Khunger M, Hernandez AV, Pasupuleti V, Rakshit S, Pennell NA, Stevenson J, et al. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1\/PD-L1 axis inhibitors: a systematic review and meta-analysis. JCO Precis Oncol. 2017;1:1\u201315.","journal-title":"JCO Precis Oncol"},{"issue":"14","key":"14575_CR29","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2217\/fon-2021-1184","volume":"18","author":"R Woodford","year":"2022","unstructured":"Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, et al. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncol. 2022;18(14):1793\u20139.","journal-title":"Future Oncol"},{"issue":"3","key":"14575_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","volume":"42","author":"L Yuan","year":"2021","unstructured":"Yuan L, Tatineni J, Mahoney KM, Freeman GJ. VISTA: a mediator of quiescence and a promising target in cancer immunotherapy. Trends Immunol. 2021;42(3):209\u201327.","journal-title":"Trends Immunol"},{"issue":"1","key":"14575_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","volume":"14","author":"J Liu","year":"2021","unstructured":"Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, et al. Targeting B7\u2013H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol OncolJ Hematol Oncol. 2021;14(1):21.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"8","key":"14575_CR32","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, et al. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27(8):2411-2425.e9.","journal-title":"Cell Rep"},{"issue":"16_suppl","key":"14575_CR33","doi-asserted-by":"publisher","first-page":"TPS5097","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5097","volume":"40","author":"MN Stein","year":"2022","unstructured":"Stein MN, Dorff TB, Goodman OB, Thomas RA, Silverman MH, Guo M, et al. A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(16_suppl):TPS5097\u2013TPS5097.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"14575_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/JCO.2024.42.4_suppl.18","volume":"42","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Azad A, Carles J, Matsubara N, Oudard S, Saad F, et al. CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42(4_suppl):18\u201318.","journal-title":"J Clin Oncol"},{"issue":"13","key":"14575_CR35","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/1078-0432.CCR-15-2512","volume":"22","author":"M Hussain","year":"2016","unstructured":"Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2016;22(13):3192\u2013200.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"14575_CR36","first-page":"778","volume":"82","author":"J Volmink","year":"2004","unstructured":"Volmink J, Siegfried N, Robertson K, G\u00fclmezoglu AM. Research synthesis and dissemination as a bridge to knowledge management: the Cochrane Collaboration. Bull World Health Organ. 2004;82(10):778\u201383.","journal-title":"Bull World Health Organ"},{"issue":"24","key":"14575_CR37","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14575-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14575-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14575-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:01:30Z","timestamp":1757235690000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14575-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14575"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14575-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable as the study involves secondary data from published articles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1173"}}